Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Spectranetics (SPNC) Share Price

News articles about Spectranetics (NASDAQ:SPNC) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spectranetics earned a news impact score of 0.02 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 45.4252180463122 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Spectranetics (SPNC) opened at $38.45 on Tuesday. The firm has a market cap of $1,680.00, a PE ratio of -24.18 and a beta of 1.54. Spectranetics has a 12 month low of $19.80 and a 12 month high of $38.55. The company has a debt-to-equity ratio of 7.61, a quick ratio of 1.43 and a current ratio of 1.92.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at

About Spectranetics

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.

Insider Buying and Selling by Quarter for Spectranetics (NASDAQ:SPNC)

What are top analysts saying about Spectranetics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spectranetics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit